NICE's diagnostics guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34) makes recommendations on tumour profiling tests for oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer.

This guidance will assess use of the tests for ER-positive, HER2-negative cancer that has spread to the lymph nodes (LN-positive early breast cancer). DG34 will be withdrawn and replaced with new guidance which will include recommendations on tumour profiling tests for LN-positive early breast cancer and the existing recommendations on tumour profiling tests for LN-negative early breast cancer.